Pumitamig

Other Medications

6 Clinical Trials

Description

Pumitamig is an investigational medication currently being studied as a potential treatment for colorectal cancer. It is being evaluated in clinical trials, specifically in patients with previously untreated, unresectable, or metastatic colorectal cancer. The trials are comparing pumitamig in combination with chemotherapy to bevacizumab (Avastin) in combination with chemotherapy. Pumitamig is being studied in patients whose tumors have specific characteristics, such as a BRAF mutation (specifically V600E) or are MSI-H (microsatellite instability-high). The goal of these trials is to assess the safety and effectiveness of pumitamig in this setting.

Mechanism of Action

Pumitamig is being investigated for its potential role in treating colorectal cancer. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is being tested in combination with standard chemotherapy regimens to see if it can improve outcomes compared to existing treatments like bevacizumab plus chemotherapy.

Side Effects

As pumitamig is an investigational drug Its side effects are still being evaluated in ongoing clinical trials. The most common side effects and their severity are not yet fully known. Participants in the trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07221357 Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Ch
NCT07070232 Phase 1
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
United States, Australia, Belgium, Germany, Italy, Spain, Turkey (Türkiye), Unit
NCT07079631 Phase 1
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
United States, Germany, Japan, Spain, United Kingdom
NCT06618287 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
United States, Australia, Canada, Chile, France, Italy, Netherlands, Spain, Unit
NCT04895709 Phase 1
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
United States, Australia, Canada, Germany, Israel, Italy, Japan, Spain
NCT07492680 Phase 2
Not yet recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
United States, Belgium, Canada, China, France, Germany, Hong Kong, Ireland, Ital

Quick Info

CategoryOther Medications
Clinical Trials6
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
783 trials
Leucovorin
Other Medications
644 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.